Prevalence and nature of potential drug-drug interactions among hospitalized HIV patients presenting with suspected meningitis in Uganda

Keyphrases

• HIV Patients 100%
• Uganda 100%
• Cryptococcal Meningitis 100%
• Drug Interactions 100%
• Meningitis 100%
• Potential Drug-drug Interactions 100%
• Clinical Decisions 66%
• Antiviral Drugs 66%
• QT Prolongation 66%
• Drug Combination 66%
• Drug Interaction Checkers 66%
• Clinical Outcomes 66%
• Opportunistic Infections 33%
• Tuberculosis 33%
• Single Patient 33%
• People Living with HIV (PLHIV) 33%
• Co-infection 33%
• Efavirenz 33%
• Retrospective Review 33%
• Hospitalization 33%
• Resource-limited Settings 33%
• Therapeutic Drug Monitoring 33%
• Fluconazole 33%
• Dissonance 33%
• Cotrimoxazole 33%
• Increased Vulnerability 33%
• Potential Interaction 33%
• Multiple Drugs 33%
• Patients Included 33%
• Tuberculous Meningitis 33%
• Mean Frequency 33%
• Rifampin 33%
• Kampala Uganda 33%
• Drug Pair 33%
• Background Management 33%
• Internet Drugs 33%
• Drug Reference 33%
• Liverpool 33%
• University of Liverpool 33%
• Polypharmacotherapy 33%
• Micromedex 33%
• Adverse Clinical Outcomes 33%
• One Percent 33%

Medicine and Dentistry

• Meningitis 100%
• Human Immunodeficiency Virus 100%
• Drug Interaction 100%
• Prevalence 100%
• Cryptococcal Meningitis 60%
• QT Prolongation 40%
• Drug Interaction Checker 40%
• Combination Drug 40%
• Opportunistic Infection 20%
• Drug Therapy 20%
• Clinician 20%
• Clinical Decision Making 20%
• Fluconazole 20%
• Trimethoprim/Sulfamethoxazole 20%
• Mixed Infection 20%
• Rifampicin 20%
• Therapeutic Drug Monitoring 20%
• Tuberculous Meningitis 20%
• Efavirenz 20%

Pharmacology, Toxicology and Pharmaceutical Science

• HIV 100%
• Drug-Drug Interaction 100%
• Prevalence 100%
• Meningitis 100%
• Cryptococcal Meningitis 60%
• Drug Interaction Checker 40%
• QT Prolongation 40%
• Combination Drug 40%
• Efavirenz 20%
• Opportunistic Infection 20%
• Cotrimoxazole 20%
• Mixed Infection 20%
• Tuberculous Meningitis 20%
• Rifampicin 20%
• Fluconazole 20%
• Therapeutic Drug Monitoring 20%